ArticleBioorganic & medicinal chemistry2007
A kit method for the high level synthesis of [211At]MABG.
Article in Bioorganic & medicinal chemistry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 61 citations in OpenAlex.
- Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.Medicinal research reviews · 2026Review
- Production ofEJNMMI radiopharmacy and chemistry · 2025Article
- Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.EJNMMI radiopharmacy and chemistry · 2024Review
- The Different Strategies for the Radiolabeling of [Pharmaceutics · 2024Review
- Therapeutic efficacy ofChemical science · 2023Article
- Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals.Nuclear medicine and molecular imaging · 2019Review
- Current Consensus on I-131 MIBG Therapy.Nuclear medicine and molecular imaging · 2018Review
- Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.Targeted oncology · 2018Review
- Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.Molecules (Basel, Switzerland) · 2018Review
- Norepinephrine Transporter as a Target for Imaging and Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Review
- Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.Cancer biotherapy & radiopharmaceuticals · 2013Review
- A convenient Simple Method for Synthesis of Meta-iodobenzylguanidine (MIBG).Iranian journal of pharmaceutical research : IJPR · 2013Article
- Promising therapeutic targets in neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Review
- Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.Current radiopharmaceuticals · 2011Review
- Astatine Radiopharmaceuticals: Prospects and Problems.Current radiopharmaceuticals · 2008Article
- Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
meta-[(211)At]Astatobenzylguanidine ([(211)At]MABG), an analogue of meta-iodobenzylguanidine (MIBG) labeled with the alpha-emitter (211)At, targets the norepinephrine transporter. Because MABG has been shown to have excellent characteristics in preclinical studies, it has been considered to be a promising targeted radiotherapeutic for the treatment of tumors such as micrometastatic neuroblastoma that overexpress the norepinephrine transporter. To facilitate clinical evaluation of this agent, a convenient method for the high level synthesis of [(211)At]MABG that is adaptable for kit formulation has been developed. A tin precursor anchored to a solid-support was treated with a methanolic solution of (211)At in the presence of a mixture of H(2)O(2)/HOAc as the oxidant; [(211)At]MABG was isolated by simple solid-phase extraction. By using C-18 solid-phase extraction, the radiochemical yield from 25 batches was 63+/-13%; however, loss of radioactivity during evaporation of the methanolic solution was a problem. This difficulty was avoided by use of a cation exchange resin cartridge for isolation of [(211)At]MABG, which resulted in radiochemical yields of 63+/-9% in a shorter duration of synthesis. The radiochemical purity was more than 90% and no chemical impurity has been detected. The final doses were sterile and apyrogenic. These results demonstrate that [(211)At]MABG can be prepared via a kit method at radioactivity levels anticipated for initiation of clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.